# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `ocfix_study-forensics-032_Claude_Opus_ac46ae`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:27:57.218099+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Opus
**Winner:** Claude Opus — **70.3/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight
**Forensic flags:** 1
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Opus | 30.0/30 | 2.4/8 | 5.4/8 | 4.8/6 | 3.6/6 | 4.5/6 | 1.6/8 | 8.0/8 | 0.0/10 | 10.0/10 | **70.3/100** |

## Study Forensics Audit

### Claude Opus

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization

## Reasoning Integrity Audit

### Claude Opus
**Classification:** Correct and well-supported
**Load-bearing steps:** 1 / 5

## Mechanism Analysis

### Claude Opus
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Opus
Conclusion claims: 1
- Direct support: 0
- Indirect support: 1
- Unsupported: 0
- Contradicted: 0


## Forensic Flags

### Claude Opus

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Opus

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 2.4/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 1 supporting, 0 mentioned / 5
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 5.4/8
  - (+) `steps[4]`: "Applied priority rule: Active selling of clinical benefit ('transform outcomes') with promotional language makes this ov"
    _Most informative reasoning step_
  - Note: 5 reasoning steps
  - Note: Low step utility: 1/5 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "No cardiovascular events were tracked means no heart attacks, strokes, or deaths were measured"
    _Most substantive assumption_
  - Note: 3/3 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[0]`: "Whether regulatory agencies accept LDL as a surrogate endpoint for accelerated approval"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.9"
    _Stated confidence level_
  - (-) `uncertainties[0]`: "Whether regulatory agencies accept LDL as a surrogate endpoint for accelerated approval"
    _Listed but never addressed in reasoning_
  - Note: 2 uncertainties (2 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[0]`: "mechanism_vs_evidence - could argue this is primarily about tier mismatch"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 1.6/8
  - (+) `self_check[1]`: "Verified the overclaim vs mechanism_vs_evidence decision - promotional language tips toward overclaim"
    _Most substantive self-verification step_
  - (-) `self_check[0]`: "Confirmed this is not solid - clear mismatch between evidence and claims"
    _Fluff self-check_
  - Note: 3 self-check items
  - Note: Self-check quality: 0 deep, 1 arithmetic, 2 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.78, 221 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "tory agencies accept ldl as a surrogate endpoint for accelerated approval the"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Opus

**MODERATE:**
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether regulatory agencies accept LDL as a surrogate endpoi...' is listed but not addressed
  - `uncertainties[0]`: "Whether regulatory agencies accept LDL as a surrogate endpoint for accelerated approval"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Opus

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/11 content words)
  - `key_claims[0]`: "Company claims cardiovascular protection and transformed outcomes based solely on 12-week biomarker "
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/6 content words)
  - `key_claims[1]`: "No cardiovascular events were measured, yet cardiovascular benefit is strongly implied"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/12 content words)
  - `key_claims[2]`: "The promotional language ('major breakthrough', 'transform outcomes') actively sells clinical benefi"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 1 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[0]`: "Whether regulatory agencies accept LDL as a surrogate endpoint for accelerated approval"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "mechanism_vs_evidence - could argue this is primarily about tier mismatch"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "solid - if we accepted that LDL reduction alone justifies the claims"


## Agent Profiles

### Claude Opus (claude-opus-4-20250514)
**Parse OK:** True | **Latency:** 16165ms

**Final Answer:** overclaim

**Confidence:** 0.9

**Assumptions:**
- The Phase 2 trial was properly conducted and the 65% LDL reduction is accurate
- The trial only measured biomarkers (LDL cholesterol) and safety, not clinical outcomes
- No cardiovascular events were tracked means no heart attacks, strokes, or deaths were measured

**Reasoning Steps:**
1. Identified evidence tier: biomarker study (LDL cholesterol levels only)
2. Identified conclusion tier: human therapeutic outcomes (heart attacks, strokes)
3. Found bridge step: jumping from cholesterol reduction to cardiovascular event prevention
4. Evaluated language: 'major breakthrough in cardiovascular protection' and 'transform outcomes' are strong promotional claims
5. Applied priority rule: Active selling of clinical benefit ('transform outcomes') with promotional language makes this overclaim rather than mechanism_vs_evidence

**Key Claims:**
- Company claims cardiovascular protection and transformed outcomes based solely on 12-week biomarker data
- No cardiovascular events were measured, yet cardiovascular benefit is strongly implied
- The promotional language ('major breakthrough', 'transform outcomes') actively sells clinical benefit beyond the evidence

**Alternative Hypotheses:**
- mechanism_vs_evidence - could argue this is primarily about tier mismatch
- solid - if we accepted that LDL reduction alone justifies the claims

**Uncertainties:**
- Whether regulatory agencies accept LDL as a surrogate endpoint for accelerated approval
- The exact wording of the company announcement vs. interpretation

**Self-Verification:**
- Confirmed this is not solid - clear mismatch between evidence and claims
- Verified the overclaim vs mechanism_vs_evidence decision - promotional language tips toward overclaim
- The company is not just implying benefit but actively selling it as established

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 2.4/8 `###.......`
- Structural Reasoning: 5.4/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 1.6/8 `##........`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Opus** scored **70.3/100**.

**Best per dimension:**
- Correctness: Claude Opus (30.0/30)
- Support Strength: Claude Opus (2.4/8)
- Structural Reasoning: Claude Opus (5.4/8)
- Assumption Discipline: Claude Opus (4.8/6)
- Uncertainty Handling: Claude Opus (3.6/6)
- Alternative Hypothesis Quality: Claude Opus (4.5/6)
- Self Monitoring Quality: Claude Opus (1.6/8)
- Insight Depth: Claude Opus (8.0/8)
- Mechanism Quality: Claude Opus (0.0/10)
- Communication Efficiency: Claude Opus (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Opus | 16.2s | 70.3/100 | 4.3 |

Failure modes observed: decorative_uncertainty, missed_key_insight.
